Zacks Investment Research downgraded shares of VERMILLION INC (VRML) from OUTPERFORM to NEUTRAL on January 15, 2013, with a target price of $1.70.
Vermillion, Inc. is engaged in the discovery, development and commercialization of novel diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. The Company has diagnostic programs in oncology, hematology, cardiology and women's health. Its tests are intended to guide decisions regarding patient treatment, which may include decisions to refer patients to specialists, to perform additional testing, or to assist in the selection of therapy. Vermillion also intends to address clinical questions related to early disease detection, treatment response, monitoring of disease progression, prognosis and others. Its lead product includes the OVA1 ovarian tumor triage test, which addresses presurgical identification of women who are at high risk of having a malignant ovarian tumor. In addition to the OVA1 Test, Vermillion has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease. Vermillion, Inc. is based in Fre
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on VERMILLION INC (VRML),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment